Literature DB >> 14738458

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia.

M Pinder1, W H H Reece, M Plebanski, P Akinwunmi, K L Flanagan, E A M Lee, T Doherty, P Milligan, A Jaye, N Tornieporth, R Ballou, K P M J McAdam, J Cohen, A V S Hill.   

Abstract

Vaccination of malaria-naive humans with recombinant RTS,S/AS02, which includes the C-terminus of the circumsporozoite protein (CS), has been shown to induce strong T cell responses to both the whole protein antigen and to peptides from CS. Here we show that strong T cell responses were also observed in a semi-immune population in The Gambia, West Africa. In a Phase I study, 20 adult male volunteers, lifelong residents in a malaria-endemic region, were given three doses of RTS,S/AS02 at 0, 1 and 6 months. Responses to RTS,S, hepatitis B surface antigen and peptides from CS were tested using lymphocyte proliferation, interferon (IFN)-gamma production in microcultures, and IFN-gamma ex vivo and cultured ELISPOT, before and after vaccination. Cytotoxic responses were tested only after vaccination and none were detected. Before vaccination, the majority of the volunteers (15/20) had detectable responses in at least one of the tests. After vaccination, responses increased in all assays except cytotoxicity. The increase was most marked for proliferation; all donors responded to RTS,S after the third dose and all except one donor responded to at least one peptide after the second or third dose. There was a lack of close association of peptide responses detected by the different assays, although in microcultures IFN-gamma responses were found only when proliferative responses were high, and responses by cultured ELISPOT and proliferation were found together more frequently after vaccination. We have therefore identified several peptide-specific T cell responses induced by RTS,S/AS02 which provides a mechanism to investigate potentially protective immune responses in the field.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738458      PMCID: PMC1808944          DOI: 10.1111/j.1365-2249.2004.02371.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

Authors:  A Lalvani; P Moris; G Voss; A A Pathan; K E Kester; R Brookes; E Lee; M Koutsoukos; M Plebanski; M Delchambre; K L Flanagan; C Carton; M Slaoui; C Van Hoecke; W R Ballou; A V Hill; J Cohen
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

2.  A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

Authors:  J F Doherty; M Pinder; N Tornieporth; C Carton; L Vigneron; P Milligan; W R Ballou; C A Holland; K E Kester; G Voss; P Momin; B M Greenwood; K P McAdam; J Cohen
Journal:  Am J Trop Med Hyg       Date:  1999-12       Impact factor: 2.345

3.  Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays.

Authors:  K L Flanagan; E A Lee; M B Gravenor; W H Reece; B C Urban; T Doherty; K A Bojang; M Pinder; A V Hill; M Plebanski
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

4.  Malaria in a peri-urban area of The Gambia.

Authors:  S W Lindsay; H Campbell; J H Adiamah; A M Greenwood; J E Bangali; B M Greenwood
Journal:  Ann Trop Med Parasitol       Date:  1990-12

5.  Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule.

Authors:  M F Good; D Pombo; I A Quakyi; E M Riley; R A Houghten; A Menon; D W Alling; J A Berzofsky; L H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

6.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

7.  Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children.

Authors:  E M Riley; S J Allen; S Bennett; P J Thomas; A O'Donnell; S W Lindsay; M F Good; B M Greenwood
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Sep-Oct       Impact factor: 2.184

8.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

Authors:  K E Kester; D A McKinney; N Tornieporth; C F Ockenhouse; D G Heppner; T Hall; U Krzych; M Delchambre; G Voss; M G Dowler; J Palensky; J Wittes; J Cohen; W R Ballou
Journal:  J Infect Dis       Date:  2001-01-24       Impact factor: 5.226

9.  Hepatitis B virus infection in two Gambian villages.

Authors:  H C Whittle; A K Bradley; K McLauchlan; A B Ajdukiewicz; C R Howard; A J Zuckerman; I A McGregor
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

10.  Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells.

Authors:  J Geginat; F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  27 in total

1.  Discovering naturally processed antigenic determinants that confer protective T cell immunity.

Authors:  Pavlo Gilchuk; Charles T Spencer; Stephanie B Conant; Timothy Hill; Jennifer J Gray; Xinnan Niu; Mu Zheng; John J Erickson; Kelli L Boyd; K Jill McAfee; Carla Oseroff; Sine R Hadrup; Jack R Bennink; William Hildebrand; Kathryn M Edwards; James E Crowe; John V Williams; Søren Buus; Alessandro Sette; Ton N M Schumacher; Andrew J Link; Sebastian Joyce
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

2.  Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.

Authors:  Geert Leroux-Roels; Isabel Leroux-Roels; Frédéric Clement; Opokua Ofori-Anyinam; Marc Lievens; Erik Jongert; Philippe Moris; W Ripley Ballou; Joe Cohen
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

Authors:  Elizabeth H Nardin; Giane A Oliveira; J Mauricio Calvo-Calle; Kristiane Wetzel; Carolin Maier; Ashley J Birkett; Pramod Sarpotdar; Michael L Corado; George B Thornton; Annette Schmidt
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.

Authors:  V Ann Stewart; Shannon M McGrath; Patrice M Dubois; Maria G Pau; Pascal Mettens; Joseph Shott; Michelle Cobb; J Robert Burge; David Larson; Lisa A Ware; Marie-Ange Demoitie; Gerrit Jan Weverling; Babak Bayat; Jerome H H V Custers; Marie-Claude Dubois; Joe Cohen; Jaap Goudsmit; D Gray Heppner
Journal:  Infect Immun       Date:  2007-02-16       Impact factor: 3.441

5.  Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.

Authors:  Arnoldo Barbosa; Denise Naniche; John J Aponte; M Nelia Manaca; Inacio Mandomando; Pedro Aide; Jahit Sacarlal; Montse Renom; Sarah Lafuente; W Ripley Ballou; Pedro L Alonso
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

6.  Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.

Authors:  Amir Horowitz; Julius C R Hafalla; Elizabeth King; John Lusingu; Denise Dekker; Amanda Leach; Philippe Moris; Joe Cohen; Johan Vekemans; Tonya Villafana; Patrick H Corran; Philip Bejon; Chris J Drakeley; Lorenz von Seidlein; Eleanor M Riley
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

7.  T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution?

Authors:  Amadu Jalloh; Muctarr Jalloh; Hiroyuki Matsuoka
Journal:  Malar J       Date:  2009-06-05       Impact factor: 2.979

8.  MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines.

Authors:  Tamara K Berthoud; Susanna J Dunachie; Stephen Todryk; Adrian V S Hill; Helen A Fletcher
Journal:  J Immunol Methods       Date:  2008-10-24       Impact factor: 2.303

9.  Characterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals.

Authors:  Thanh V Nguyen; John B Sacci; Patricia de la Vega; Chandy C John; Anthony A James; Angray S Kang
Journal:  Malar J       Date:  2009-10-23       Impact factor: 2.979

10.  Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Authors:  Mark E Polhemus; Shon A Remich; Bernhards R Ogutu; John N Waitumbi; Lucas Otieno; Stella Apollo; James F Cummings; Kent E Kester; Christian F Ockenhouse; Ann Stewart; Opokua Ofori-Anyinam; Isabelle Ramboer; Conor P Cahill; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Amanda Leach; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.